Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Shipra Rastogi"'
Autor:
Mark Lebwohl, Andrew Blauvelt, Shipra Rastogi, Radhakrishnan Pillai, Robert J. Israel, April W. Armstrong, Sylvia Hsu, Stephen K. Tyring, Richard G. Langley
Publikováno v:
British Journal of Dermatology. 180:306-314
Background Brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, has demonstrated superior efficacy and safety over ustekinumab as induction therapy for moderate-to-severe psoriasis. Objectives To evaluate the efficacy and saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b73152183edc65a2af5adba71b2b0719
https://doi.org/10.1111/bjd.17318
https://doi.org/10.1111/bjd.17318
Publikováno v:
Dermatology and Therapy
Introduction Clinical trials have shown brodalumab to have better efficacy than ustekinumab for the treatment of moderate-to-severe psoriasis. An estimation of the cost-effectiveness of brodalumab vs. ustekinumab is warranted and may be useful for tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::317137974bbb03e330c2d38e76a542b8
https://doi.org/10.1007/s13555-018-0251-4
https://doi.org/10.1007/s13555-018-0251-4
Autor:
Steven R. Feldman, Jashin J. Wu, Jay Lin, Melissa Lingohr-Smith, Brandy Menges, Shipra Rastogi
Publikováno v:
Journal of Dermatological Treatment. 29:769-774
To compare the cost-effectiveness of the newly approved biologic drug, brodalumab, with other commonly used biologics for the treatment of moderate-to-severe psoriasis in the United States.An economic model was constructed in Excel to compare average
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b477e21250a09231d195b124bb26b040
https://doi.org/10.1080/09546634.2018.1466022
https://doi.org/10.1080/09546634.2018.1466022
Autor:
Radhakrishnan Pillai, Robert J. Israel, Sylvia Hsu, Kenneth B. Gordon, Leon H Kircik, Boni E. Elewski, Lawrence F. Eichenfield, Shipra Rastogi, Alice B. Gottlieb
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 32:1305-1313
BACKGROUND Patients with psoriasis have lesional symptoms, including itch, which can reduce quality of life. The efficacy and safety of brodalumab, an interleukin-17 receptor A antagonist, in treating moderate-to-severe psoriasis have been reported i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57f57871b95af1d90d8d12fb92b0113b
https://doi.org/10.1111/jdv.14913
https://doi.org/10.1111/jdv.14913
Autor:
Radhakrishnan Pillai, Shipra Rastogi, Sylvia Hsu, Mark Lebwohl, Lawrence J. Green, Andrew Blauvelt, Varsha Bhatt, Robert Israel, Kim A. Papp
Publikováno v:
Journal of the American Academy of Dermatology. 77:372-374
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::578b3896bf9ec0671ce7cc2378b6d21f
https://doi.org/10.1016/j.jaad.2017.03.026
https://doi.org/10.1016/j.jaad.2017.03.026
Publikováno v:
American journal of clinical dermatology. 20(2)
Data on treatment outcomes in patients with psoriasis who have skin of color are limited. Brodalumab has shown efficacy in patients with moderate-to-severe plaque psoriasis. Our objective was to evaluate the efficacy, safety, and health-related quali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d28e64895b9ed15762d33a1e6b460de
https://pubmed.ncbi.nlm.nih.gov/30471012
https://pubmed.ncbi.nlm.nih.gov/30471012
Autor:
Alice B. Gottlieb, Shipra Rastogi, Kim A. Papp, Richard G. Langley, Radhakrishnan Pillai, Kenneth B. Gordon, Robert J. Israel, Mark Lebwohl
Publikováno v:
The British journal of dermatology. 179(2)
BACKGROUND Biologics are being used increasingly to treat moderate-to-severe psoriasis. Efficacy may differ in patients with previous exposure to biologics. OBJECTIVES To investigate the impact of previous biologic exposure on the efficacy and safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1dd91c1fdfd9094ecbc4f7ab84ca2bd
https://pubmed.ncbi.nlm.nih.gov/30141552
https://pubmed.ncbi.nlm.nih.gov/30141552
Autor:
Shipra Rastogi, Melissa Lingohr-Smith, Brandy Menges, Steven R. Feldman, Jashin J. Wu, Jay Lin
Publikováno v:
Journal of medical economics. 21(5)
Brodalumab is a new biologic approved by the US Food and Drug Administration in 2017 for the treatment of moderate-severe psoriasis. This study evaluated the impact of the introduction of brodalumab on the pharmacy budget on US commercial health plan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b4a22c88df4f9bf49eb202d7eb0af82
https://pubmed.ncbi.nlm.nih.gov/29357713
https://pubmed.ncbi.nlm.nih.gov/29357713
Autor:
Richard G. Langley, A.W. Armstrongi, Shipra Rastogi, Sylvia Hsu, Radhakrishnan Pillai, Robert J. Israel, Mark Lebwohl, Andrew Blauvelt, Stephen K. Tyring
Publikováno v:
British Journal of Dermatology. 180:e40-e40
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7858c0220f0711730f5b342de33b2492
https://doi.org/10.1111/bjd.17471
https://doi.org/10.1111/bjd.17471
Autor:
Stephane Fauverghe, Steven Bernstein, Brian Kinney, Nicolo Scuderi, Shipra Rastogi, John S. Sampalis, Andreas Nikolis
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology
Andreas Nikolis,1 Steven Bernstein,2 Brian Kinney,3 Nicolo Scuderi,4 Shipra Rastogi,5 John S Sampalis61Victoria Park, Plastic Surgery Section, Westmount, QC, Canada; 2Dermatology Department, University of Montreal Health Centre, Montreal, QC, Canada;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd3d6b84c07779cd3e9cc710d90bd149
https://www.dovepress.com/a-randomized-placebo-controlled-single-blinded-split-faced-clinical-tr-peer-reviewed-article-CCID
https://www.dovepress.com/a-randomized-placebo-controlled-single-blinded-split-faced-clinical-tr-peer-reviewed-article-CCID